Related Experiment Videos
Integrative oncology for young adults with cancer: A prospective pragmatic controlled trial
Eran Ben-Arye1,2,3, Shahar Samuel4, Ilit Turgeman5,6
1Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. eranben@technion.ac.il.
Abstract:
Research on the impact of integrative oncology (IO) programs on quality of life (QoL) among young adults with cancer is limited. The present study explored the impact of a patient-tailored IO program for young patients undergoing active oncology care. This pragmatic, prospective and preference-controlled study examined patients aged 18-45 referred by oncology healthcare providers to an IO consultation and 6 weekly treatments addressing QoL-related concerns. High adherence to integrative care (high-AIC, vs. low-AIC) was defined as attending ≥ 4 IO sessions, with baseline and 6-week symptoms assessed using ESAS (Edmonton Symptom Assessment Scale); EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) and MYCAW (Measure Yourself Concerns and Wellbeing) tools. Of 180 patients, 137 (76%) were high-AIC, with similar baseline demographic, cancer-and QoL-related characteristics in both groups. At 6 weeks, high-AIC patients reported greater improvement on ESAS (p = 0.046) and MYCAW (p = 0.008) wellbeing; ESAS nausea (p = 0.027); EORTC dyspnea; and EORTC role functioning (p = 0.031). Significant within-group improvement was observed in older high-AIC patients (aged 40-45, n = 72), as opposed to no improvement in young high-AIC patients (aged 18-39, n = 65) on ESAS fatigue (p = 0.033), anxiety (p = 0.001), and breathing (p = 0.016); and wellbeing on ESAS (p = 0.006) and MYCAW (p < 0.001). Young patients with cancer highly adherent to a 6-week IO program reported significantly improved wellbeing, more significantly among older patients. Further research is needed to explore the impact of IO programs on young patients with cancer, addressing their unique psychological, social, and spiritual needs.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Clinical Trials: Overview
Targeted Cancer Therapies
There are several types of targeted therapies against specific...